Get the latest tech news
Promising early data in triple negative breast cancer
BioNTech explores a bispecific for the “next generation” of immune checkpoint therapy.
New data suggests researchers may have found one of their most promising candidates yet for the next generation in immunotherapy drugs — bispecific antibodies targeting two key proteins in cancer, PD1 or PD-L1 and VEGF. The research builds on the 1990s discovery of immunotherapy drugs called checkpoint inhibitors, which was “transformative” in oncology, BioNTech co-founder and CMO Özlem Türeci told STAT. Experts told STAT at the time that the results were “striking” and “impressive,” though they recommended caution about the data until investigators can show that the drug extended life, a key measure in oncology research called overall survival.
Or read this on r/technology